Our products use targeted radiation to better inform treatment decisions and deliver personalised therapy in areas of significant unmet medical need.
Telix is a global, commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals.
Telix’s extensive pipeline for urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning is underpinned by a strong global supply, manufacturing and distribution network.
Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent and has more than 18 clinical trials underway worldwide.
Latest News
See all
Sean Healy is a husband, father and financial services professional from Richmond Virginia, who was diagnosed with stage 3 clear cell renal cell carcinoma (ccRCC) in 2018. We spoke to him about his diagnosis, his journey through treatment, and why he believes the need for more options in kidney cancer has never been more…
Read more
